JPWO2022010847A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022010847A5 JPWO2022010847A5 JP2022578860A JP2022578860A JPWO2022010847A5 JP WO2022010847 A5 JPWO2022010847 A5 JP WO2022010847A5 JP 2022578860 A JP2022578860 A JP 2022578860A JP 2022578860 A JP2022578860 A JP 2022578860A JP WO2022010847 A5 JPWO2022010847 A5 JP WO2022010847A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- isolated antibody
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 238000011467 adoptive cell therapy Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049012P | 2020-07-07 | 2020-07-07 | |
| US63/049,012 | 2020-07-07 | ||
| PCT/US2021/040445 WO2022010847A1 (en) | 2020-07-07 | 2021-07-06 | Mic antibodies and binding agents and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532852A JP2023532852A (ja) | 2023-08-01 |
| JPWO2022010847A5 true JPWO2022010847A5 (enExample) | 2024-07-10 |
Family
ID=77127088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578860A Pending JP2023532852A (ja) | 2020-07-07 | 2021-07-06 | Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12139539B2 (enExample) |
| EP (1) | EP4178678A1 (enExample) |
| JP (1) | JP2023532852A (enExample) |
| KR (2) | KR20230152783A (enExample) |
| CN (1) | CN116249716A (enExample) |
| AU (1) | AU2021305084A1 (enExample) |
| CA (1) | CA3184940A1 (enExample) |
| TW (1) | TW202216776A (enExample) |
| WO (1) | WO2022010847A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023076883A1 (en) * | 2021-10-27 | 2023-05-04 | Samyang Biopharm Usa Inc. | Anti-mic antibodies with variant fc domains |
| WO2023225626A2 (en) * | 2022-05-20 | 2023-11-23 | Adanate, Inc. | Multi-targeting lilrb antibodies and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| AU4226999A (en) | 1998-06-02 | 1999-12-20 | Dendreon Corporation | Method for preparation and (in vivo) administration of antigen presenting cell composition |
| US20030167531A1 (en) | 1998-07-10 | 2003-09-04 | Russell Douglas A. | Expression and purification of bioactive, authentic polypeptides from plants |
| US6512162B2 (en) | 1998-07-10 | 2003-01-28 | Calgene Llc | Expression of eukaryotic peptides in plant plastids |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| BR0014945A (pt) | 1999-10-21 | 2004-08-31 | Monsanto Co | Modificação pós-traducional de proteìnas recombinantes produzidas em plantas |
| WO2001039594A2 (en) | 1999-12-03 | 2001-06-07 | Dendreon Corporation | Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| CA2403964C (en) | 2000-03-30 | 2013-04-30 | Dendreon Corporation | Compositions and methods for dendritic cell-based immunotherapy |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| EP2330201B1 (en) | 2003-10-22 | 2017-04-05 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| EP2314618A3 (en) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US20080196111A1 (en) | 2005-03-18 | 2008-08-14 | Innate Pharma S.A. | Expression Vectors and Methods for Obtaining Nk Cell Specific Expression |
| WO2008036981A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Research, Inc. | Methods for treating mica-related disorders |
| ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| WO2012091756A1 (en) | 2010-12-30 | 2012-07-05 | Avidbiotics Corp. | Non-natural mic proteins |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
| PE20142361A1 (es) | 2011-09-30 | 2015-01-16 | Dana Farber Cancer Inst Inc | Peptidos terapeuticos |
| SG11201404177PA (en) | 2012-02-07 | 2014-08-28 | Innate Pharma | Mica binding agents |
| WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP3666886A1 (en) | 2013-03-15 | 2020-06-17 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP6450381B2 (ja) * | 2013-07-05 | 2019-01-09 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体 |
| EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
| CN106459917B (zh) | 2014-04-23 | 2021-03-09 | 朱诺治疗学股份有限公司 | 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法 |
| EP3145953A1 (en) | 2014-05-21 | 2017-03-29 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti bip or anti mica antibodies |
| WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| SG11201703203RA (en) | 2014-10-20 | 2017-05-30 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| TWI718118B (zh) | 2015-01-16 | 2021-02-11 | 美商奇諾治療有限公司 | 針對ｒｏｒ１之特異性抗體及嵌合抗原受體 |
| WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| US20180355318A1 (en) | 2015-04-29 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| JP2018517415A (ja) | 2015-06-10 | 2018-07-05 | ナントクエスト インコーポレイテッド | がんを処置するための改変ｎｋ−９２細胞 |
| TN2018000187A1 (en) | 2015-12-04 | 2019-10-04 | Dana Farber Cancer Inst Inc | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
| AU2016366677A1 (en) | 2015-12-09 | 2018-07-26 | Nantcell, Inc. | Compositions and methods for treatment of HER2 positive metastatic breast cancer |
| AU2017344411A1 (en) | 2016-10-19 | 2019-05-09 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
| JP2019535250A (ja) | 2016-10-29 | 2019-12-12 | ジェネンテック， インコーポレイテッド | 抗ｍｉｃ抗体及び使用方法 |
| CN110418839B (zh) | 2017-03-08 | 2023-06-09 | 免疫生物公司 | 用于临床的修饰的NK-92haNK003细胞 |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| WO2019004550A1 (ko) | 2017-06-26 | 2019-01-03 | 강원대학교 산학협력단 | Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도 |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| AU2018311096A1 (en) | 2017-08-04 | 2020-01-30 | Nantkwest, Inc. | Treating and inhibiting leukemia with NK-92 cells |
| ES2992909T3 (en) | 2017-08-09 | 2024-12-19 | Juno Therapeutics Inc | Methods and compositions for preparing genetically engineered cells |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| CN113056484B (zh) | 2018-07-31 | 2025-01-14 | 库利南Mica公司 | 阻断mica/b脱落的抗mica/b抗体及其使用方法 |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| AU2019366960A1 (en) * | 2018-10-23 | 2021-05-27 | Vor Biopharma, Inc. | Fc silenced antibody drug conjugates (ADCs) and uses thereof |
| US20220288225A1 (en) | 2019-08-23 | 2022-09-15 | Northwestern University | Materials and methods for activating antigen-specific t cell responses |
| WO2023076883A1 (en) | 2021-10-27 | 2023-05-04 | Samyang Biopharm Usa Inc. | Anti-mic antibodies with variant fc domains |
-
2021
- 2021-07-06 KR KR1020237036123A patent/KR20230152783A/ko active Pending
- 2021-07-06 KR KR1020227046132A patent/KR102594083B1/ko active Active
- 2021-07-06 CA CA3184940A patent/CA3184940A1/en active Pending
- 2021-07-06 WO PCT/US2021/040445 patent/WO2022010847A1/en not_active Ceased
- 2021-07-06 CN CN202180047612.4A patent/CN116249716A/zh active Pending
- 2021-07-06 AU AU2021305084A patent/AU2021305084A1/en active Pending
- 2021-07-06 EP EP21748734.7A patent/EP4178678A1/en active Pending
- 2021-07-06 JP JP2022578860A patent/JP2023532852A/ja active Pending
- 2021-07-06 TW TW110124764A patent/TW202216776A/zh unknown
-
2022
- 2022-10-25 US US18/049,434 patent/US12139539B2/en active Active
-
2024
- 2024-10-08 US US18/909,119 patent/US20250026837A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JPWO2019224717A5 (enExample) | ||
| JPWO2019173420A5 (enExample) | ||
| FI3802608T3 (fi) | Cd3-vasta-aineita ja niiden käyttötapoja | |
| JP2020534351A5 (enExample) | ||
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| JPWO2019224718A5 (enExample) | ||
| JP2022507485A (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| JP2020522280A5 (enExample) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JPWO2021104302A5 (enExample) | ||
| CN109071671B (zh) | Erbb2靶向抗体 | |
| JPWO2019170898A5 (enExample) | ||
| JPWO2021170068A5 (enExample) | ||
| JPWO2020210067A5 (enExample) | ||
| JPWO2022010847A5 (enExample) | ||
| JPWO2020227457A5 (enExample) | ||
| JPWO2020205331A5 (enExample) | ||
| JPWO2019170885A5 (enExample) | ||
| JPWO2021213475A5 (enExample) | ||
| JPWO2023078382A5 (enExample) | ||
| JPWO2020218951A5 (enExample) | ||
| JPWO2023051683A5 (enExample) | ||
| JPWO2022242681A5 (enExample) | ||
| JPWO2021170071A5 (enExample) |